Emerging Therapeutic Agents for Colorectal Cancer

Marianna Nalli; Michela Puxeddu; Giuseppe La Regina; Stefano Gianni; Romano Silvestri

doi:10.3390/molecules26247463

Emerging Therapeutic Agents for Colorectal Cancer

Molecules. 2021 Dec 9;26(24):7463. doi: 10.3390/molecules26247463.

Authors

Marianna Nalli¹, Michela Puxeddu¹, Giuseppe La Regina¹, Stefano Gianni², Romano Silvestri¹

Affiliations

¹ Department of Drug Chemistry and Technologies, Sapienza University of Rome, 00185 Rome, Italy.
² Department of Biochemical Sciences "Rossi Fanelli", Institute of Biology and Molecular Pathology of CNR, Sapienza University of Rome, 00185 Rome, Italy.

Abstract

There are promising new therapeutic agents for CRC patients, including novel small-molecule inhibitors and immune checkpoint blockers. We focused on emerging CRC's therapeutic agents that have shown the potential for progress in clinical practice. This review provides an overview of tyrosine kinase inhibitors targeting VEGF and KIT, BRAF and MEK inhibitors, TLR9 agonist, STAT3 inhibitors, and immune checkpoint blockers (PD1/PDL-1 inhibitors), for which recent advances have been reported. These new agents have the potential to provide benefits to CRC patients with unmet medical needs.

Keywords: CRC; anticancer agents; cancer; emerging targets.

Publication types

Review

MeSH terms

Colorectal Neoplasms* / drug therapy
Colorectal Neoplasms* / enzymology
Humans
Molecular Targeted Therapy*
Neoplasm Proteins* / antagonists & inhibitors
Neoplasm Proteins* / metabolism
Protein Kinase Inhibitors* / chemistry
Protein Kinase Inhibitors* / therapeutic use

Substances

Neoplasm Proteins
Protein Kinase Inhibitors

Abstract

Publication types

MeSH terms

Substances

Grants and funding